Clinical trial
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine…
NCT00460850 · Hoffmann-La Roche, Industry · Terminated
Key facts
| NCT number | NCT00460850 |
|---|---|
| Title | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B. |
| Official title | An Open Label Study to Evaluate the Effect of PEGASYS on ALT and HBV DNA Levels in Patients With Lamivudine-Resistant HbeAg-Negative Chronic Hepatitis B |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis B, Chronic |
| Intervention type | Drug |
| Interventions | peginterferon alfa-2a (40KD) [PEGASYS] |
| Enrollment | 60 |
| Start date | Sep 1, 2007 |
| Completion | Jun 1, 2008 |
| First posted | Apr 17, 2007 |
| Last update posted | Jun 30, 2008 |
| Countries | Turkey (Türkiye) |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: